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ll. ABSTRACT 
The aim of this study was to evaluate the factors contributing towards erectile 
dysfunction (ED) in patients followed-up in the Institut Urologi & Nefrologi, Hospital 
Kuala Lumpur between 1st. March 1999 to 31st. August 1999. One hundred and fifty-
four patients were included in this study. The mean age of the patients was 52.68 years. 
The youngest was 22 and the oldest was 76 year-old. Most were between the age of 45 
and 65 year-old. 
Diabetes mellitus and hypertension played a major role as contributing factors in the 
overall study population. 45.4% of the patients have diabetes mellitus and 29.2% have 
hypertension. 41.5% of the patients have single contributing factor towards erectile 
dysfunction whereas 29.2% have two and 10.4% of the patients have three contributing 
factors. In 18.2% of the studied patients the cause of ED were unknown. In term of 
racial distribution, Malays contributed 48.7% of the study sample; Indian 25.3% and 
Chinese constitute about 22.1 %. 
35 patients who fulfilled the inclusion criteria were enrolled in the clinical trial with 
transurethral alprostadil (MUSE®). Thirty patients (85.6%) completed the in-clinic 
titration phase. Of these, 18 patients (60%) responded well to the MUSE® and they 
were sent home with the medication. However only 33.3% of patients completed the 
home phase. 
In conclusion, diabetes mellitus plays an important role in our patients with erectile 
dysfunction and MUSE® is one of the alternative treatment for such condition. 
m. ABSTRAK 
Tujuan penyelidikan ini adalah untuk menilai factor-faktor yang menyumbang ke arah 
'erectile dysfuction' atau pemyakit mati pucuk di atas pesakit-pesakit yang dirawat di 
Institut Urologi dan Nefrologi, Hospital Kuala Lumpur di antara 1 hb Mac hingga 31 hb 
Ogos, 1999. Seramai seratus limapuluh empat pesakit terlibat dalam penyelidikan ini. 
Purata umur pesakit adalah 52.68 tabun dengan yang termuda 22 tahun dan tertua 76 
tahun. Kebanyakan daripada pesakit ini berumur di antara 45 dan 65 tahun. 
Kencing manis dan darah tinggi memainkan peranan yang penting dalam keseluruhan 
sample penyelidikan. Seramai 45.5% menghidap kencing manis and 29.2% menghidap 
darah tinggi. Seramai 41.50/0 daripada pesakit=pesakit ini mempunyai satu factor yang 
menyumbang ke arah penyakit ini, 29.2% mempunyai dua factor penyumbang dan 
10.4% dengan tiga factor penyumbang sementara 18.2% lagi tidak diketahui 
penyebabnya. Pesakit Melayu merangkumi 48.7% dari sample, sementara pesakit India 
seramai 25.3% dan Cina merangkumi 22.1 %. 
Tigapuluh-Iima pesakit yang menepati syarat telah mengambil bahagian dalam kajian 
MUSE®. Tigapuluh pesakit (85.6%) menamatkan peringkat klinik. Lapanbelas 
daripadanya (60%) memberikan tindakbalas yang baik terhadap MUSE® dan 
seterusnya pulang dengan dos yang tertentu. Walaubagaimanapun hanya 33.30/0 
daripada mereka menamatkan peringkat di rumah. Kesimpulannya, kencing Manis 
memainkan peranan penting dalam pesakit kita ke arab menyumbang kepada penyakit 
'erectila dysfunction'. MUSE®. Adalah salah satu rawatan altematif kepada pesakit-
pesakit ini. 
4.6 Erectile dysfunction associated with systemic 
diseases 
4.7 Psychogenic causes 
5.0 DIAGNOSIS OF ERECTILE DYSFUNCTION 
5.1 Special Investigations 
5.1.1 Nocturnal peniJe tumescence 
5.1.2 Doppler ultrasonography 
5.1.3 Dynamic infusion cavemosometry & 
cavemosography (DICC) 
5.1.4 Internal pudendal arteriography 
5.1.5 Radionuclide examination 
5.1.6 Neurophysiological test 
5.1.7 Penile plethysmography 
5.1.8 Penile biopsy 
5.1.9 Cavernous oxygen tension monitoring 
6.0 TREATMENT OF ERECTILE DYSFUNCTION 
6.1 Oral medication 
6.1.1 Oral sildenafil 
6.1.2 Oral yohimbine 
6.2 Intracavernous injection with vasoactive drugs 
6.3 Topical cream and paste 
32 
33 
34 
38 
38 
41 
42 
43 
43 
44 
44 
45 
45 
46 
47 
47 
48 
48 
50 
6.4 Transurethral PGE 1 51 
6.5 Surgical treatment of erectile dysfunction 52 
6.5.1 Vascular surgery 52 
6.5.2 Penile prosthesis 54 
6.6 Vacuum constriction devices 54 
6.7 Hormonal treatment 55 
6.8 Psychological therapy 56 
7.0 MATERIALS & METHODS 57 
7.1 Period of study 57 
7.2 Study background 58 
7.3 Study population 59 
7.4 Inclusion & exclusion criteria 59 
7.5 Clinical endpoint 61 
7.6 Schedule of study visit 61 
7.6.1 Screening visit 61 
7.6.2 Titration phase 62 
7.6.3 Maintenance phase (3 months) 64 
7.7 Study exit 65 
7.8 Dose change after start of treatment 65 
7.9 Laboratory evaluation 66 
7.10 Adverse events 66 
7.11 Study termination 67 
7.12 Data collection and analysis' 67 
Vl1 
7.13 Clinical supplies 68 
7.13.] Study medication 68 
7.13.2 Packaging & labeling 68 
7.13.3 Medication storage 68 
7.13.4 Medication accountability 69 
7.14 Concomitant medication 69 
7.15 Indemnity insurance 69 
7.16 Publication policy 70 
7.17 Ethical consideration 70 
7.17.1 Ethic committee 70 
7.17.2 Declaration of Helsinki 70 
7.17.3 Subject informed consent 70 
7.18 Adverse events reporting 71 
8.0 RESULTS 
8.1 Epidemiology 72 
8.1.1 Racial distribution 72 
8.1.2 Age distribution 72 
8.1.3 Duration of erectile dysfunction 75 
8.1.4 Predisposing factor( s) toward ED 75 
8.2 Responses in clinic 77 
8.3 Responses at home 80 
Vlll 
9.0 DISCUSSION 
9.1 In-clinic Titration Phase 
9.2 Home phase 
10.0 CONCLUSION 
11.0 REFERENCES 
IX 
86 
90 
94 
97 
98 
v. LIST OF ABBREVIATIONS 
ACTH adrenocorticotrophin hormone 
cGW> 3' , 5' -cycl ic guanosine monophosphate 
CGRP calcitonin-gene-related peptide 
DICC dynamic infusion cavernosometry and 
cavemosography 
EAS Erection assessment scale 
ED Erectile dysfunction 
EEG electroencephalography 
EMG electromyography 
GABA y-amino-butyric acid 
GTN Glyceryl trinitrate 
leI Intracavemous injection 
IUN Institut Urologi dan Nefrologi 
HKL Hospital Kuala Lumpur 
MMAS Massachusetts Male Aging Study 
MPON Medial preoptic nucleus 
MSH melanocyte stimulating hormone 
MUSE® Medicated urethral system for erection 
NANC nonadrenergic noncholinergic 
NO Nitric oxide 
NOS Nitric oxide synthase 
NPT Nocturnal penile tumescence 
PGEI Prostaglandin E 1 
x 
PVN 
REM 
VIP 
5-HT 
Paraventricular nucleus 
rapid eye movement 
Vasoactive intestinal peptide 
5-hydroxytryptamine 
Xl 
IV. LIST OF TABLES 
Table Title Page 
Table 6.1 Treatment options for erectile dysfunction 46 
Table 7.1 Erection assessment scale 63 
Table 7.2 Level of discomfort 63 
Table 8.1 The characteristics of ED patients in IUN, HKL from 1st 76 
March to 31 8t August, 1999 
Table 8.2 N umber of contributing factor( s) towards ED in our patients in 77 
IUN, HKL from 1 st March to 31 st August 1999 
Table 8.3 The characteristics of patients in in-clinic titration phase 78 
Table 8.4 The characteristics of patients in home phase 81 
Table 8.5 Results of trial with MUSE® in !UN, HKL from 1st March to 84 
31 st August, 1999 
XlI 
Vll. LIST OF FIGURES 
Figure Title Page 
Figure 3.1 Structure of penis 5 
Figure 3.2 Cross-sectional anatomy of the penis 6 
Figure 3.3 Arterial supply to the penis 9 
Figure 3.4 The cavemosal sinusoids 10 
Figure 3.5 Venous drainage of the penis 11 
Figure 3.6 Nerves supply of the penis 12 
Figure 3.7 The cavemosal sinusoids during erection 15 
Figure 5.1 Examples of normal RigiScan tracing and abnormal 40 
RigiScan tracing 
Figure 7.1 The MUSE® device before (left) and after (right) depression 58 
of the button. The alprostadil pellet is visible at the tip of the 
device 
Figure 7.2 The MUSE® device inserted into the urethra 59 
Figure 8.1 Racial distribution among erectile dysfunction patients in 73 
!UN, HKL from 1 st March to 31 st August, 1999 
Figure 8.2 Age distribution of erectile dysfunction patients seen in ruN, 74 
HKL from 1 st March to 31 st August 1999 
Figure 8.3 Pie chart showing percentage of patients who completed the 79 
in-clinic titration phase and those who did not completed this 
phase 
Figure 8.4 Pie chart showing the outcome of patients who completed 80 
the in-clinic titration phase 
XliI 
Figure 8.5 
Figure 8.6 
Figure 8.7 
Racial distribution of patients in home phase 
Distribution of patients who either had previous treatment 
for ED or not 
Dosages ofMUSE® used for home phase 
X]V 
82 
82 
83 
VIII. ACKNOWLEDGEMENT 
I wish to express my gratitude and appreciation to my supervisor, Dr Zainal Mahamood 
for his guidance and supervision in the preparation of this dissertation and also for his 
patience he bears on me till this work was completed. I would also like to thank Mr. 
Sahabudin Raja Mohamed for letting me involved in this study and also to other 
consultant urologist in the ION namely Mr. KhairulIah, Mr. Kumaresan, Mr. Rohan 
Malik, Mr. Murali Sundram and other trainee urologist, namely Mr. Murali Mohan, Mr. 
Yoong, Mr. Lee and Mr. Sritharan who made my urology training very exciting. 
I would also like to take this opportunity to thank my Head of Department, Dr. Abdul 
Hamid Mat Sain for his inspiring comments and guidance and for having taught the 
meaning of discipline and sacrifice during my training. 
I would also like to express my appreciation to Dr. Myint Tun, Dr. Ahmad Zahari, Dr. 
Mohd Shaiful, Dr. Mohd Nor Gohar and Dr. Anas for their guidance during my 
training. Special thanks to Associate Professor Dr. Jafri Malin Dato' Abdullah, 
Associate Professor Hashim Ibrahim and Dr. Ahmad Sukari for training me in their 
subspecialities. 
I am also thankful for the guidance given to me by the surgeons in Hospital Kota Bharu 
especially Mr. Imran Khalid, Mr. Nik Azim, Mr. Othman Md Zain, Mr. Faisal Ismail, 
Mr. Nik Shukri and not to forget, the head of surgical department, Hospital Kota Bharu, 
Mr Hasim Mohamed. 
xv 
Lastly, I would like to thank Miss Michelle and Janssen & Cilag for sponsoring the 
drugs, which made this trial possible. To all the staff of Institut Urologi & Nefrologi, 
Hospital, Kuala Lumpur, thanks you for all the assistance. Also to all my colleagues, 
who made my training more colourful, to Dr. Farouk and Dr. Kamal who gave 
encouraging support for me to finish my dissertation. 
XVI 
IX. DEDICATION 
I dedicate this dissertation to my late mother, Allahyarhamah Raja Maimunah Bt. 
Raja Ahmad, who was the first person that wished me to become a doctor. To my 
father, 'I want to make you happy'. 
Last but not least, I wished to thank my wife, Nik Norliza Bt. Nik Hassan and my 
family for an their support and patience. To my sons, Mohd Danial Adha and 
Mohamad Noor Farhan, 'one day, you'll understand why I'm so busy now'. 
XVll 

1.0 INTRODUCTION 
Until a few years ago, what we now refer to as erectile dysfunction was often and 
erroneously called impotence. However, impotence has bad connotations. People relate 
sterility, premature ejaculation and a host of other sexual problem to the tenn. In 1992, 
the National Institute of Health Consensus Panel has defined erectile dysfunction as 
inability to achieve or maintain erection sufficient for satisfactory sexual function. 1, 2, 3 
Historical1y, the prevalence of erectile dysfunction has been difficult to estimate due to 
the fact that it is not life threatening, and the patients often do not seek treatment. 
However in 1948, a historical starting point for epidemiological data on the prevalence 
of erectile dysfunction started when Kinsey et al from United States did a study on 
15,781 people whose age ranged from 10 to 80 years. He concluded that the prevalence 
of erectile dysfunction was less than 1% in people age below 30 years, less than 3% in 
people below 45 years, 6.7% between 45 to 55 years, 25% at 65 years and 80% at 80 
years. However, these has to be interpreted with caution because out of 15,781 people, 
only 4108 were more than 25 year-old and only 306 were above 55.3 
In 1990, Spector and Carey reviewed 23 studies done from 1948 till 1988 and he found 
that the prevalence of erectile dysfunction is between 4 to 9% in the community study. 3 
Diokno e/ a/ (1990) said that prevalence of erectile dysfunction is 35% in people age 
above 60 years and it is significantly associated with heart attack, urinary incontinence 
. 3 
and the use of sedatIves. 
More recently, Feldman et al (1994) using the result of Massachusetts Male Aging 
Study from 1987 to 1989 on 1290 non institutionalized men age 40 to 70 years in 11 
randomly selected cities in Boston, Massachusetts found that the prevalence of 
minimal, moderate and complete erectile dysfunction were 170/0, 25% and 10% 
respectively. Base on this study, US population projection till 2005 estimated that there 
will be more than 50 million people age between 40 and 70 years and out of these, 
erectile dysfunction will affect 25 million people. There will be 39% of 40 years men 
and 67% of 70 year-old man with erectile dysfunction. In term of degree of erectile 
dysfunction, 5% of 40 year-old man and 15% of 70 year-old man will have complete 
erectile dysfunction. 17% of 40 year-old and 34% of 70 year-old man will have 
moderate erectile dysfunction and 170/0 of man age 40 and 70 will have minimal 
erectile dysfunction 4. 
lonler et af (1995) screened 1517 people age above 40 years and he found that 129 
(8.5%) of them had no erection for the past 12 months. Out of 1,388 people, who have 
erection, 12.4% of them has erection in less than 1 in 5 times of sexual stimulation and 
19.7% has erection in less than half the time. He also noted that the prevalence was 
significantly associated with age and lowered quality of life. 3 
However, only a few studies on prevalence of erectile dysfunction were done outside 
USA. In 1986, a small study on 109 people age more than 16 years in United Kingdom 
found that 32% of them had difficulty in achieving an erection and 20% had difficulty 
in maintaining an erection. Shirai et af (1987) from Japan noted the prevalence of 
erectile dysfunction was 260/0 and Solstad et al (1993) did a study on 411 Danish age 51 
years and he found that the prevalence was 19%.3 
2 
Erectile dysfunction is a common disorder that most often occurs in association with 
diseases such as diabetes, hypertension, prostate cancer (as a consequence of surgery or 
anti-androgen therapy), vascular disease, neurological or spinal cord disease. While 40-
90% of erectile dysfunction involves an organic component, psychological 
complications may contribute to or result from erectile dysfunction. 
Although several treatments are available for erectile dysfunction, including vacuum 
erection devices, surgery (penile implant and vascular reconstruction), penile injection 
of vasoactive compounds, and recently introduced oral sildenafil; (Viagra) most 
patients still remain untreated. The threshold at which a man will seek treatment for 
erectile dysfunction has been high, because of social stigma and lack of convenient, 
safe and effective treatment. Previous studies conducted in the USA have shown that 
transurethral alprostadil, MUSE® which is a prostaglandin El is well tolerated and 
effective in the treatment of men with organic erectile dysfunction.22 Although one of 
the trials ofMUSE® involved a large group of patients, the dose was not selected by an 
open-label stepwise titration, as would be expected in clinical practice, and the study 
population was homogenous because all study sites were in the USA. Thus the 
conclusion from that study may not be applicable to a culturally diverse Malaysia. 
Thus we conducted an open label study with MUSE®. This trial is conducted to 
confirm the efficacy and safety of transurethral alprostadil in multicultural eastern 
study population and to identify demographic factors that might influence the patients' 
response to therapy. The endpoints measured in this part of the study included erectile 
response on a five-point scale, sexual intercourse, patient comfort with the therapy, and 
adverse reactions. 
3 
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2.0 AIMS OF THE STUDY 
2.1 To study the characteristics of patients with erectile dysfunction in Institut 
Urologi & Nefrologi (IUN), Hospital Kuala Lumpur (HKL). 
2.2 To evaluate the safety and efficacy of transurethral alprostadil (MUSE®) in the 
treatment of patients with erectile dysfunction. 
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3.0 ANATOMY AND PHYSIOLOGY OF ERECTION 
3.1 Anatomy of the penis 
The penis can be described in term of structural component, vascular anatomy and 
neuroanatomy. 
3.1.1 Structural component 
The penis is a cylindrical organ consisting of: -
a) The base 
b) The body and 
The glans penis. (Figure 3.1) 
lett c rus 
Crura penis 
1 right crus -
Membranous urethra 
Bulb of the penis 
COTPUS spunglosurn 
Corpus 
cavernosum 
Glans peniS 
Figure 3.1 Structure of penis (adapted from Erectile Dysfunction. Current 
investigation and management by Ian Eardley and Krishna SetlJia. 1998) 
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The base is attached to the bony pelvis and consists of the crura and the bulb. The 
paired crura are cylindrical structures attached to the ischial and the pubic rami. They 
meet in the midline where they become the corpora carvenosa. The ischiocavemous 
muscles cover them posteriorly. The bulb, which contains the urethra, pierces the 
urogenital diaphragm between the crura. It narrows anteriorly as the corpus 
spongiosum, where it comes to lie inferiorly or ventral to the corpora carvenosa and is 
covered by bulbocarvenous muscles. The body of penis is thus made up of three tubular 
structures, the paired corpora carvenosa and the inferiorly placed corpus spongiosum. 
Di stally the corpus spongiosum is expanded to become the glans penis, within which 
the two corpora carvenosa terminate. 
Dorsa l peni le arte ry '.~._ 
Deep dorsal vein ----,-;;;6'.!Bl~ 
Corpus 
cavernOSlim 
Corpus spong 
Urethra 
Superfic ial dorsal vein 
Dorsa l nerve of 
the penis 
Dartos fascia 
Buck's fascia 
Circumflex veins 
Tunica albuginea 
Cavernosal artery 
Urethral artery 
Figure 3.2 Cross-sectiollal allatomy o{tlte peflis (adapted from Erectile Dysfullctioll. 
Currellt illvestigatioll alld mallagement by Iall Eardley alld Krishfla Sethia. 1998) 
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The paired corpora carvenosa are surrounded by a dense fibrous sheath, the tunica 
albuginea. (Figure 3.2) The corpus spongiosum lies outside the tunica. The tunica 
albuginea is tough, fibrous and relatively indistensible. It is composed primarily of 
collagen and elastin, and traditionally is divided into two: an outer longitudinal layer, 
which surrounds both corpora, and an inner circular layer, which surrounds each 
individual corporal body. In the midline these two layers are fused and form a midline 
septum, which is incomplete distally. Inside the tunica lies the spongy tissue, which is 
essentially a vascular structure. Interconnecting sinusoidal spaces are surrounded by 
trabeculae containing smooth muscle cells which themselves lie in a stroma composed 
of collagen, elastin, blood vessels and nerves. The trabecular spaces are lined by 
endothelium and are fed by the helicine branches of the deep penile arteries. The corpus 
spongiosum has a similar anatomy although its tunica is much thinner (and is absent on 
the glans penis), while the sinusoidal spaces are larger. 
On the dorsum of the penis are found the main neurovascular structures, namely the 
deep dorsal vein in the midline, flanked laterally by the dorsal penile arteries and the 
dorsal nerves of the penis. (Figure 3.2) These structures are enclosed by a condensation 
of the deep fascia, known as Buck's fascia, which is cylindrical prolongation of Colles' 
fascia. Superficial to this is the superficial dorsal vein of the penis, which lies within 
the loose superficial fascia which is itself covered by a rather thin, loose skin. 
The penis is supported by two fascial ligaments. The fundiform ligament, which is a 
condensation of deep fascia, extends inferiorly from the linea alba and divides into two 
bands which enclosed the penis before meeting ventral to the shaft of the penis. Here 
they become confluent with the deep fascia of the scrotum. The suspensory ligament of 
7 
the penis is a short triangular ligament from the pubic symphysis to the deep fascia on 
the dorsum of the penis. It is this ligament that suspends the erect penis into a position 
perpendicular to the body, when a man is standing. 
3.1.2 Vascular anatomy 
Arterial supply of the penis 
The arterial supply of the penis is from the internal iliac artery via the pudendal artery. 
(Figure 3.3) The latter leaves Alcock's fascial canal on the medial aspect of the 
obturator intemus muscle and divides into the superficial perineal (scrotal) artery and 
continues as penile artery. It then pierces the urogenital diaphragm before dividing into 
its terminal branches, the dorsal penile artery, the cavemosal arteries (deep branch) and 
the bulbar artery. The bulbar artery supplies the bulb of the penis and the corpus 
spongiosum before passing to the glans. The cavernosal arteries provide most of the 
blood supply for the spongy tissue of the corpora carvenosa. The terminal branches are 
of two sorts: the coiled helicine arteries, which directly supply the sinusoidal spaces, 
and few smaller arterioles, which travel within the trabeculae. The helicine arteries are 
the main resistance vessels of the penis and control flow into the cavemosal sinusoids. 
When the penis is flaccid the main arterial flow is through the trabecular arteries and 
the helicine arteries are short, coiled and closed. During erection the blood is diverted 
into the helicine arteries, which elongate and dilate, thereby filling the sinusoidal 
spaces. 
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The dorsal penile arteries travel distally to the glans penis where they anastomose with 
the terminal branches of the artery to the bulb. As they pass distally they give off 
circumflex branches, which pass with the circumflex veins around the penis. 
Pudendal-----I--..... .. ~~---­
artery 
Dorsal artery'---""" 
Deep artery----#-...,., 
Spongeous~~~~~~---J 
artery 
Artery to the bulb 
Figure 3.3. Arterial supply to the penis 
There are often communication between the deep and the dorsal arterial systems, and 
occasionally a significant proportion of the cavemosal blood supply can be derived 
from the superficial penile arteries. It may be the circumflex arteries, which provide the 
structural basis for the communication. Occasionally there is an accessory arterial 
supply to the penis from obturator artery or even the external iliac artery. 
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Venous drainage of the penis 
From the sinusoidal spaces, venous blood collects in a series of subtunical plexus, 
which lie beneath the tunica albuginea. These plexus drain via emissary veins, which 
pierce the tunica albuginea. (Figure 3.4) Distally, the emissary veins drain either into 
spongiosal veins or into circumflex veins, which in tum drain into the deep dorsal vein. 
Proximally, the emissary veins drain into the cavernous veins or crural veins, which 
then drain into the internal pudendal vein. (Figure 3.5) 
-Tunica albuginea 
" . _ . " 
Figure 3.4 Tile cavertlosal sinusoids (adapted from Erectile Dysfunction. Current 
investigation and management by Jan Eardley and Krishna Sethia, 1998) 
The venous drainage of the glans penis is via a number of small veins which form a 
retrocoronal plexus from which the deep dorsal veins arises. The corpus spongiosum is 
drained by the spongiosal and bulbar veins into the deep dorsal vein. The deep dorsal 
vein travels proximally in the midline to pierce the suspensory ligament before passing 
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between the puboprostatic 1 igaments to enter the peri-prostatic venous plexus. The 
superficial dorsal venous complex drains the skin and the subcutaneous tissues of the 
penis and usually drains into the saphenous vein. 
Circumflex 
veins Deep 
Su perficia l 
dorsa l vein 
Corpus 
cavernosum 
dorsal vein Caverno us Peri-prostatic 
Retrocoronal 
p lexus 
Spongiosa l 
veins 
ve in plexus 
Bul ba r 
I 
Internal 
pudendal 
vein vein 
Corpus Crura l 
spongiosum veins 
Figure 3.5 Venous drainage of tile penis (adapted (rom Erectile Dysfullctioll. 
Currelll investigation and management bv lall Eardley alld Krishna Sethia. 1998) 
3.l.3 Nerve supply of the penis 
The innervations of the penis are both autonomic (sympathetic and parasympathetic) 
and somatic (sensory and motor). The parasympathetic innervation of the penis is the 
primary erecti le innervation. It comes from the intermediolateral column of the sacral 
spinal cord and exits via the nerve root of S2, S3 and S4 to travel in the nervi erigentes 
11 
to the pelvic plexus, where some of them are joined by the sympathetic nerves from the 
. h . 1 25 M fi supenor ypogastnc p exus. ost tbers then synapse and post-synaptic fibers pass in 
the cavernous nerves to the penis. (Figure 3.6) 
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l Sympathetic chain lnieri~rf _ ...---~-.-..oT11 
mesenteric .. - I 
plexus ~.-··---t--o T12 A'·· ... ...... 
J t"""', ..... ..,.,,--_...... ----0 L 1 
Sup~fior y( ._ .. --...... -;..---0 12 
hypogamric • ". .. -'---
plexus ' 
\ S 
. \ 0 .. 2 
Hypogastric " 
.: narves '., o~'i\'I.~ 
" , s4'"h 
/( .-..... \ 0" ! 1"~ 
"- ' ~1. '\ 
I \ \ Pel";,, j;·r' -·1 
\--
I \ plexlU; A"'N -: 
. I!ti:.r ~/' erv. I 
_ ~. erigerrje:: 
/i-:' .. CavernDus .. .-1 
External " .... nerve /.;0'/ 
.... --.-- :I' 
sphincter >--_._-- ~~ 
>------..... ;;:::::-::;.,.-" 
.,.~."'-"-
//- Pudendal nerve 
i 
, Dors~ nerve of penis 
Figure 3.6. Nerves SUpply o(the penis 
Sympathetic nerves originate within the thoracolumbar cord (TII-L2) and then pass via 
ventral nerve roots and sympathetic chain to the hypogastric plexus before reaching the 
pelvic plexus. 13 Some fibers travel via lumbar splanchnic nerves to the inferior 
mesenteric and superior hypogastric plexus. At this level there is considerable 
opportunity for integration with the parasympathetic innervation. Post-synaptic fibers 
then pass within the cavernous nerves to the penis. The cavernous nerve is important to 
surgeons, because of its relationship to the prostate, since it is at risk of damage during 
12 
open prostatectomy, radical excision of the rectum, or bladder. A clear understanding 
of these nerves is essential to prevent iatrogenic ED. Stimulation of the pelvic plexus 
and the cavernous nerves induce erection, whereas stimulation of the hypogastric nerve 
or sympathetic trunk causes detumescence. 
The sensory innervation of the penis has a number of peculiar characteristics. For 
instance the glans penis has a receptor density that is higher than any other area of the 
body, with most nerves having free endings. The ratio of free nerve endings and the 
corpuscular receptors are 10: 1. Physiologically the receptors of the glans have a high 
tactile threshold and a low pain threshold, compared with glabrous skin, which has the 
opposite characteristics. Afferent information is carried mainly via AfJ and C fibers 
within the dorsal nerve of the penis and pudendal nerve, spinal cord and spinothalamic 
tract to the thalamus and sensory cortex for sensory perception. Efferent fibers are also 
present in the pudendal nerve, and provide the motor supply for the ischiocavernosus 
and bulbocavernosus muscles. 
3.2 Hemodynamic and mechanism of erection and detumescence 
3.2.1 Corpora Cavemosa 
The penile erectile tissue, specifically the cavernous smooth musculature and the 
smooth muscles of the arteriolar and arterial walls, plays a key role in the erectile 
process. In the flaccid state, these muscles are tonically contracted under influenced by 
the sympathetic discharge, which is more predominant, and vasoconstrictors secreted 
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by endothelium allowing only a small amount of arterial flow for nutritional purposes 
(1.4 to 4.0 ml per minute per lOOgm of tissue ). 
Psychic stimuli (received or generated in the brain) or physical stimuli of the genital 
organ causes transmission of nerve impulses from the spinal cord to the cavernous 
nerves (via autonomic nervous system) thereby releasing neurotransmitter.! This results 
in relaxation of these smooth muscles and the following events where by Lue et al in 
San Francisco identified 8 separate phases of erection 56. 
Phase 0: The flaccid phase 
The penis is flaccid under predominantly sympathetic neural tone. The arterial inflow is 
low (typically less than 15cmfsec) and the trabecular smooth muscle is contracted. 
Blood gases are similar to venous blood. (Figure 3.4) 
Phase 1: The filling phase 
Parasympathetic stimulation leads to arteriolar dilatation with a massive increase in 
arterial flow to greater than 30cmlsec. Sinusoids filled without any significant increase 
in intracavemosal pressure. 
Phase 2: The tumescent phase 
The intracavemous pressure rises leading to relative fall in the arterial inflow. As 
pressure increases above diastolic blood pressure, flow continues only during the 
systolic phase. As the sinusoids expand there is some compression of the subtunical 
venous plexus. (Figure 3.7) The penis elongates and expands to its maximal capacity 
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Figure 3.7 The cavemosal sinusoids during erection (adapted from Erectile 
Dysfunction. Current investigation and management by Ian Eardley and Krishna 
Sethia. 1998 
Phase 3: The full erection phase 
The intracavernosal pressure rises to around 90% of systolic pressure. The arterial flow 
to the penis falls but still greater than in flaccid state. The sinusoid expanding and 
compressed the emissary veins. The blood gases are similar to the arterial blood. 
Phase 4: The rigid erection phase 
The ischiocavernosus muscles contracts and thus squeezing the crura and causes the 
intracavernous pressure to rise above the systolic pressure. The ischiocavernosus 
muscle can contract voluntarily or under the bulbocavernous reflex. The arterial inflow 
will cease and the emissary veins will be completely compressed and closed thereby 
fo rming the penis as a close space. This is called the 'veno-occlusive mechanism' . 
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Phase 5: The initial detumescence phase 
There is a small transient increase in the intracavernosal pressure, probably due to 
sympathetic stimulation against a closed venous outflow. 
Phase 6: The slow detumescence phase 
There is contraction of the trabecular smooth muscle and constriction of the helicine 
arterioles with a fall in the intracavemosal pressure leading to reduced compression of 
the subtunical veins and increased venous outflow. 
Phase 7: The fast detumescence phase 
Under the sympathet!c stimulation, there is a fall in both arterial inflow and 
intracavemosal pressure, with an increase in venous outflow and rapid detumescence. 
3.2.2 Corpus Spongiosum and Glans Penis 
The Hemodynamic of the corpus spongiosum and glans penis are somewhat different 
from those of the corpora cavemosa. During erection, the arterial flow increases in a 
similar manner; however, the pressure in the corpus spongiosum and glans is only one-
third to one-half that in the corpora cavemosa because the tunical covering (thin over 
the corpus spongiosum and virtually absent over the glans) ensures minimal venous 
occlusion. 
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3.3 Smooth Muscle Physiology 
Spontaneous contractile activity of cavernous smooth muscle has been recorded in vitro 
and in vivo studies, where they found two types of electrical activity recorded from the 
corpus cavemosum, i.e. spontaneous and activity-induced. Field stimulation results in a 
decrease in tension and intracellular calcium at low frequencies and an increase in 
tension and intracellular calcium at high frequencies. In general, the response to 
pharmacological agents correlates with the change in intracellular calcium. 
As described above, the cerebral impulses nonnally travel through sympathetic 
(inhibiting norepinephrine release), parasympathetic (releasing nitric oxide and 
acetylcholine), and somatic (releasing acetylcholine) pathways to produce a normal 
rigid erection. In patients with a sacral cord lesion, the cerebral impulse can still travel 
via the sympathetic pathway to inhibit norepinephrine release, and nitric oxide and 
acetylcholine can still be released via synapse with postganglionic parasympathetic and 
somatic neurons. Because the number of synapses between the thoracolumbar outflow 
and postganglionic parasympathetic and somatic neurons is less than the sacral outflow, 
the resulting erection will not be as strong. 
In men, there are three distinct types of erection present, namely psychogenic, 
reflexogenic and nocturnal. Psychogenic erection is a result of audiovisual stimuli or 
fantasy. Impulses from the brain modulate the spinal erection centers (TII-L2 and S2-
S4) to activate the erectile process. The mechanisms are thought to involve both the 
sympathetic and parasympathetic pathways. These erections can occur in men with 
complete lesions in the lumbar cord and cauda equina while sympathectomy also does 
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not lead to loss of these erections. It is common in younger men, but decrease gradually 
with increasing age. 56 
Reflexogenic erection is produced by tactile stimuli to the genital organs. This response 
is abolished by damage to the sacral spinal segments, the spinal nerve roots, the pelvic 
nerves, the pudendal nerve and the cavernous nerve. All these findings suggest the 
presence of a sacral spinal reflex with afferent fibers carried in the dorsal nerve of the 
penis and the pudendal nerve, with the efferent fibers carried within the sacral 
parasympathetic fibers. The impulses reach the spinal erection centers; some then 
follow the ascending tract, resulting in sensory perception, while others activate the 
autonomic nuclei to send messages via the cavernous nerves to the penis to induce 
erection. This type of erection can present in men with high spinal cord injury. For 
example, in men with complete thoracic lesions, reflex erections can be elicited by 
manual stimulation of the penis. In men with lesions below this, reflex erections appear 
much less frequently. It is assumed that thoracic lesions are associated with a complete 
loss of descending impulses from higher centers, while in men with lower lesions, there 
may be ischaemic damage to the sacral segments of cord, which lead to abolition of the 
reflex. 13 
Nocturnal erection occurs mostly during rapid-eye-movement (REM) sleep and it is 
usual for a potent man to have between four to six erections per night. The mechanism 
is as yet unknown. However, it is generally assumed that the presence of nonnal 
nocturnal erections indicates a diagnosis of psychogenic impotence; this need not be 
true if the pathways, which mediate the two types of erections, are different. 15. 56 
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3.4 Neurotransmitters 
3.4.1 Peripheral Neurotransmitters 
The process of erection is generally accepted to be under neuroregulatory control and 
involves the cholinergic, adrenergic and nonadrenergic noncholinergic neuroeffector 
systems. However, biochemical substances locally released from the endothelial or 
smooth muscle components of the erectile tissue may also cooperate in this function. 
Adrenergic nerve fibers and receptors have been demonstrated in the cavernous 
trabeculae and surrounding the cavernous arteries, and norepinephrine has generally 
been accepted as the principal neurotransmitter to control penile flaccidity and 
detumescence. Receptor binding studies have shown the number of a-adrenoceptors to 
be 10 times higher than the number of B-adrenoceptors. 56 
Mediators that have been proposed to function as nonadrenergic noncholinergic 
neurotransmitter include: 
1. Neuropeptides such as vasoactive intestinal peptides, calcitonin gene-related 
peptide and substance P. 
2. purines example adenosine, adenosine triphosphate. 
3. Other factors include decarboxylated amino acid, histamine, serotoni~ 
prostaglandin and bradykinin. 
Acetylcholine is required for ganglionic transmission (by nicotinic receptors) and 
] th muscle relaxation (by muscarinic receptors). Cholinergic nerves have vascu ar smoo 
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been demonstrated within the human cavernous smooth muscle and surrounding penile 
arteries, and ultra structural examination has also identified tenninals containing 
cholinergic vesicles in the same area. It has been suggested that acetylcholine 
stimulates the release of nitric oxide (NO) from endothelial cells and thus contributes 
directly to smooth muscle relaxation during erection. 8 
Latest development also found that NO as the elusive agent of penile erection. It was 
first described in 1979 as a potent relaxant of peripheral vascular smooth muscle, with 
an action mediated by cGMP. Subsequently, endothelium-derived relaxing factor was 
identified as NO or chemically unstable nitroso precursor. 14 Nitric oxide is synthesized 
from endogenous L-arginine by NO synthase (NOS) located in the vascular 
endothelium. Nitric oxide may be synthesized and released as a neurotransmitter by the 
nonadrenergic /noncholinergic (NANC) neurons after their excitation by either 
electrical or chemical stimulation. A primary biochemical role for nitric oxide is to 
stimulate the increased intracellular production of the second messenger molecule, 3', 
5' -cyclic guanosine monophosphate (cGMP). 8, 54 Recent observations strongly suggest 
that NO released from NANC neurons increases the production of cyclic guanosine 
monophosphate (cGMP), which in tum relaxes the cavernous smooth muscle via 
biochemical cascade. It has also shown that the NO-mediated responses are 
progressively inhibited as a function of decreasing oxygen tension; reverting to normal 
oxygen tension restores endothelium-dependent and neurogenic relaxation. Currently, 
NO or a NO-like substance appears to be the most likely principal neurotransmitter 
. 'le erection In this regard Ignarro et al have suggested that NO is highly 
caUSIng pent . 
1 b
O) th .c. l't cannot be stored as a preformed neurotransmitter. There are at least 
a I e; ere lore, 
.1-_ d" 0 £ nn of NOS (neuronal, endothelial and macrophage). 8,56 
Ull ee tsttnct 0 s 
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Other investigators believe that VIP may be one of the neurotransmitters responsible 
for erection. VIP-immunoreactive nerve fibers have been identified within the 
cavernous trabeculae and surrounding penile arteries, and neurostimulation-induced 
cavernous smooth muscle relaxation has been shown to be blocked by a VIP antagonist 
or anti-VIP serum. Other potential candidates include calcitonin-gene-related peptide 
(CGRP) peptide histidine methionine, pituitary adenyl ate cyclase-activating 
polypeptide 32, and prostaglandin 33,34. Prostaglandin EI receptor density is reported 
to be lower in impotent men. Although these neurotransmitters may participate in the 
erectile process, their exact role is still unclear. l• 56 Nevertheless, because of the 
multiplicity of putative transmitters present in the corpus cavemosum and in 
perivascular nerves, further investigation is needed to elucidate the interactions 
between neurotransmitters and neuromodulators at the neuromuscular junction, and 
between the neural and endothelial control of vascular tone. 
3.4.2 Central Neurotransmitters 
In animals, the hypothalamus is known to have central role in the erectile activity. 
Other important areas include the medial preoptic nucleus (MPON) and the 
paraventricular nucleus (PVN). From these nuclei there are a number of descending 
tracts, which project into the spinal nuclei which innnervate the penis. A variety of 
neurotransmitters are involved in these pathways namely catecholamines, 5-
hydroxytryptamine (S-HT), y-amino-butyric acid (GABA), oxytocin, prolactin, 
melanocyte stimulating hormone (MSH), adrenocorticotrophin (ACTH) and opioid 
neurotransmitter. In man, there are evidence that dopamine, norepinephrine, prolactin, 
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MSH and 5-HT do have a role in penile erectile activity. 56 It is suggested that 
dopaminergic and adrenergic receptors may promote sexual drive, and that serotonin 
receptors inhibit it. However, most of this evidence derived either from the animals 
studies or from the use of pharmaceutical agents in men with or without erectile 
dysfunction. 
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4.0 AETIOLOGY OF ERECTILE DYSFUNCTION 
Erectile dysfunction is a complex multifactorial syndrome, often involving both 
psychological and physiological factors (organic factors). About 20 to 30 years ago, the 
main cause of erectile dysfunction was believed to be psychogenic in origin. 3, 21 
However, in 19705 and 1980s, experts believed that erectile dysfunction always had an 
organic cause. Now, it is accepted that erectile dysfunction is commonly due to a 
complex interaction between psychological and physical problem. In anyone person, 
there may be a number of different mechanisms active at one time. In younger patient, 
it is likely that psychological cause predominates. While in men aged over 50, the 
organic causes are more common. To date, organic ED has been most frequently 
attributed to vascular abnormality (arteriogenic) and/or cavernosal (venogenic or 
venous incompetence) as well as neurogenic abnormalities. I, 3 In these cases~ 50-700/0 
result from a combination of arterial insufficiency and venous incompetence, 300/0 due 
to arterial insufficiency alone and in 15% as a result of veno-occlusive dysfunction. 
However, other causes of organic ED are currently widely recognized including 
endocrine in origin and drug-induced. Many classifications have been proposed for ED. 
Some are based on the causes such as diabetic, traumatic, prostatic carcinoma etc, while 
others are based on neurovascular mechanism of erectile process itself such as 
neurogenic, arteriogenic or venogenic. There was a new classification of ED suggested 
by D. Udelson et af (1998) that based on factors which determine erectile rigidity such 
as intracavemosal pressure, penile tissue mechanical property characteristics and penile 
geometry.II Here are some of the causes of ED. 
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4.1 Arteriogenic causes of erectile dysfunction 
Arterial disease can cause ED by restricting the inflow of blood to the penis. 
Atherosclerotic or traumatic arterial occlusive disease can reduce the perfusion pressure 
and arterial flow to the sinusoidal space and thus increasing the time needed to attain 
maximal erection and reducing the rigidity. It is also suggested that the atheroma leads 
to poor blood flow, which in turn causes relative ischaemia and impaired cavemosal 
oxygenation. This leads to smooth muscle dysfunction with associated veno-occlusive 
dysfunction. 56 Ischaemia ultimately results in loss of cavemosal smooth muscle with 
increasing fibrosis. There is also evidence that ischaemia can lead to changes in the 
structure of the tunica albuginea with alteration in the elastin and collagen content. 
These changes in structure may lead to changes in the function and efficacy of veno-
. h. 18,56 
occlUSIve mec amsm. 
Atherosclerotic disease is the cause of approximately 400/0 of ED in the men older than 
50 years.3 The cardiovascular disease can affect potency by variety of mechanism. ED 
occurs in up to 45% of patients post myocardial infarction. However, psychological 
factors also play an important role in these cases because some may not dare to exert 
himself in doing sexual intercourse. The incidence and age of onset of coronary disease 
and ED are parallel suggesting common risk factors such as hypertension, 
hyperlipidaemia, cigarette smoking and diabetes mellitus as the cause for generalized 
arteriosclerosis. Hypercholesterolemia that destroys the endothelium reduces relaxation 
of the smooth muscle cells which predisposing to ED. On the other hand, smoking can 
abolished venouS restriction ability in animal's study.18 It is also well known that 
hypertension is associated with erectile dysfunction. But it is difficult to dissociate from 
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